Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.
Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
This drug is being developed to treat a type of brain cancer, glioma. This study was designed
to determine a safe and well tolerated dose. Patients must have had prior treatment for their
glioma and be eligible for removal of their recurring tumor.